# Abituzumab in SSc-ILD

> **NCT02745145** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Systemic Sclerosis-associated Interstitial Lung Disease

## Interventions

- **DRUG:** Abituzumab 1500 mg
- **DRUG:** Abituzumab 500 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02745145
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-31
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Difficulties experienced in identifying participants who meet the eligibility criteria of the trial.
- **Last updated:** 2019-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02745145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02745145, "Abituzumab in SSc-ILD". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02745145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*